(Q33852542)

29 July 2017

1 reference

title

Cardiotoxicity of doxorubicin and other anthracycline derivatives (English)

1 reference

29 July 2017

1 reference

Jain D

1

1 reference

29 July 2017

publication date

1 January 2000

1 reference

Journal of Nuclear Cardiology

29 July 2017

published in

1 reference

29 July 2017

volume

7

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

53-62

1 reference

https://scigraph.springernature.com/pub.10.1067/mnc.2000.103324

29 July 2017

exact match

0 references

cites work

Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic

1 reference

12 December 2020

Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer

1 reference

12 December 2020

Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy

1 reference

12 December 2020

Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex

1 reference

12 December 2020

Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity

1 reference

12 December 2020

Potential cardiotoxicity with mitoxantrone

1 reference

12 December 2020

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

12 December 2020

The anthracycline antineoplastic drugs

1 reference

12 December 2020

Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer

1 reference

12 December 2020

Antineoplastic drugs in 1990. A review (Part II).

1 reference

12 December 2020

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

1 reference

12 December 2020

Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin

1 reference

12 December 2020

Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy

1 reference

12 December 2020

Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen

1 reference

12 December 2020

Dose-effect and structure-function relationships in doxorubicin cardiomyopathy

1 reference

12 December 2020

Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy.

1 reference

12 December 2020

Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline

1 reference

12 December 2020

Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration

1 reference

12 December 2020

Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation

1 reference

12 December 2020

Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies

1 reference

12 December 2020

A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.

1 reference

12 December 2020

Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.

1 reference

12 December 2020

Anthracycline cardiomyopathy monitored by morphologic changes

1 reference

12 December 2020

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

1 reference

12 December 2020

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

1 reference

12 December 2020

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

12 December 2020

Antimyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity?

1 reference

12 December 2020

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

1 reference

12 December 2020

Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals

1 reference

12 December 2020

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

1 reference

12 December 2020

Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation

1 reference

12 December 2020

Clinical status and optimal use of the cardioprotectant, dexrazoxane.

1 reference

12 December 2020

Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography

1 reference

12 December 2020

Doxorubicin-induced cardiac neurotoxicity: study with iodine 123-labeled metaiodobenzylguanidine scintigraphy

1 reference

12 December 2020

Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance

1 reference

12 December 2020

Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases

1 reference

12 December 2020

Doxorubicin-induced cardiomyopathy

1 reference

12 December 2020

Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times

1 reference

12 December 2020

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

1 reference

12 December 2020

Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect

1 reference

12 December 2020

Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity

1 reference

12 December 2020

Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes

1 reference

12 December 2020

Cytoprotective agents for anthracyclines

1 reference

12 December 2020

Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.

1 reference

12 December 2020

Cardiomyopathy of Doxorubicin in Experimental Animals. Factors Affecting the Severity, Distribution and Evolution of Myocardial Lesions

1 reference

12 December 2020

Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats

1 reference

12 December 2020

Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines

1 reference

12 December 2020

Cardiotoxicity of free and liposomally encapsulated rubomycin (daunorubicin) in mice

1 reference

12 December 2020

Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting

1 reference

12 December 2020

Doxorubicin cardiotoxicity

1 reference

12 December 2020

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

1 reference

12 December 2020

A clinicopathologic analysis of adriamycin cardiotoxicity

1 reference

12 December 2020

Taurine deficiency and doxorubicin: interaction with the cardiac sarcolemmal calcium pump

1 reference

12 December 2020

Mitoxantrone: a new anticancer drug with significant clinical activity

1 reference

12 December 2020

Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.

1 reference

12 December 2020

Subacute cardiotoxicity of adriamycin in the rat: biochemical and ultrastructural investigations

1 reference

12 December 2020

Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data

1 reference

12 December 2020

Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer

1 reference

12 December 2020

Inhibition of calcium accumulation by the sarcoplasmic reticulum: a putative mechanism for the cardiotoxicity of adriamycin

1 reference

12 December 2020

Induction of apoptosis in chronic myelogenous leukemia lymphocytes by hydroxyurea and adriamycin

1 reference

12 December 2020

Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity

1 reference

12 December 2020

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

12 December 2020

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

1 reference

12 December 2020

Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro

1 reference

12 December 2020

Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity

1 reference

12 December 2020

Prevention of anthracycline cardiotoxicity by iron chelation

1 reference

12 December 2020

Clinical pharmacokinetics of doxorubicin

1 reference

12 December 2020

Adriamycin cardiomyopathy: pathophysiology and prevention

1 reference

12 December 2020

Doxorubicin (adriamycin) cardiomyopathy

1 reference

12 December 2020

Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes.

1 reference

12 December 2020

Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration

1 reference

12 December 2020

Late cardiotoxicity after treatment for a malignant bone tumor

1 reference

12 December 2020

Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity

1 reference

12 December 2020

Adriamycin. A new anticancer drug with significant clinical activity

1 reference

12 December 2020

Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence

1 reference

12 December 2020

Identifiers

DOI

10.1067/MNC.2000.103324

1 reference

Dimensions Publication ID

29 July 2017

1035466687

0 references

1 reference